66 related articles for article (PubMed ID: 36583617)
21. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.
Robertson KA; Nalepa G; Yang FC; Bowers DC; Ho CY; Hutchins GD; Croop JM; Vik TA; Denne SC; Parada LF; Hingtgen CM; Walsh LE; Yu M; Pradhan KR; Edwards-Brown MK; Cohen MD; Fletcher JW; Travers JB; Staser KW; Lee MW; Sherman MR; Davis CJ; Miller LC; Ingram DA; Clapp DW
Lancet Oncol; 2012 Dec; 13(12):1218-24. PubMed ID: 23099009
[TBL] [Abstract][Full Text] [Related]
22. Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas.
Kim A; Gillespie A; Dombi E; Goodwin A; Goodspeed W; Fox E; Balis FM; Widemann BC
Neurology; 2009 Oct; 73(16):1273-9. PubMed ID: 19841379
[TBL] [Abstract][Full Text] [Related]
23. Association of Hearing Loss and Otologic Outcomes With Fibrous Dysplasia.
Boyce AM; Brewer C; DeKlotz TR; Zalewski CK; King KA; Collins MT; Kim HJ
JAMA Otolaryngol Head Neck Surg; 2018 Feb; 144(2):102-107. PubMed ID: 29192304
[TBL] [Abstract][Full Text] [Related]
24. NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.
Weiss BD; Wolters PL; Plotkin SR; Widemann BC; Tonsgard JH; Blakeley J; Allen JC; Schorry E; Korf B; Robison NJ; Goldman S; Vinks AA; Emoto C; Fukuda T; Robinson CT; Cutter G; Edwards L; Dombi E; Ratner N; Packer R; Fisher MJ
J Clin Oncol; 2021 Mar; 39(7):797-806. PubMed ID: 33507822
[TBL] [Abstract][Full Text] [Related]
25. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation.
Legius E; Messiaen L; Wolkenstein P; Pancza P; Avery RA; Berman Y; Blakeley J; Babovic-Vuksanovic D; Cunha KS; Ferner R; Fisher MJ; Friedman JM; Gutmann DH; Kehrer-Sawatzki H; Korf BR; Mautner VF; Peltonen S; Rauen KA; Riccardi V; Schorry E; Stemmer-Rachamimov A; Stevenson DA; Tadini G; Ullrich NJ; Viskochil D; Wimmer K; Yohay K; ; Huson SM; Evans DG; Plotkin SR
Genet Med; 2021 Aug; 23(8):1506-1513. PubMed ID: 34012067
[TBL] [Abstract][Full Text] [Related]
26. Neurofibromatosis type 1.
Gutmann DH; Ferner RE; Listernick RH; Korf BR; Wolters PL; Johnson KJ
Nat Rev Dis Primers; 2017 Feb; 3():17004. PubMed ID: 28230061
[TBL] [Abstract][Full Text] [Related]
27. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
Dombi E; Baldwin A; Marcus LJ; Fisher MJ; Weiss B; Kim A; Whitcomb P; Martin S; Aschbacher-Smith LE; Rizvi TA; Wu J; Ershler R; Wolters P; Therrien J; Glod J; Belasco JB; Schorry E; Brofferio A; Starosta AJ; Gillespie A; Doyle AL; Ratner N; Widemann BC
N Engl J Med; 2016 Dec; 375(26):2550-2560. PubMed ID: 28029918
[TBL] [Abstract][Full Text] [Related]
28. Neurofibromatosis type 1.
Anderson JL; Gutmann DH
Handb Clin Neurol; 2015; 132():75-86. PubMed ID: 26564071
[TBL] [Abstract][Full Text] [Related]
29. Characterizing the microstructural basis of "unidentified bright objects" in neurofibromatosis type 1: A combined in vivo multicomponent T2 relaxation and multi-shell diffusion MRI analysis.
Billiet T; Mädler B; D'Arco F; Peeters R; Deprez S; Plasschaert E; Leemans A; Zhang H; den Bergh BV; Vandenbulcke M; Legius E; Sunaert S; Emsell L
Neuroimage Clin; 2014; 4():649-58. PubMed ID: 24936416
[TBL] [Abstract][Full Text] [Related]
30. Audiovestibular Characteristics of Small Cochleovestibular Schwannomas in Neurofibromatosis Type 2.
Holliday MA; Kim HJ; Zalewski CK; Wafa T; Dewan R; King KA; Brewer CC; Butman JA; Asthagiri AR
Otolaryngol Head Neck Surg; 2014 Jul; 151(1):117-24. PubMed ID: 24718755
[TBL] [Abstract][Full Text] [Related]
31. Auditory temporal processing deficits and language disorders in patients with neurofibromatosis type 1.
Batista PB; Lemos SM; Rodrigues LO; de Rezende NA
J Commun Disord; 2014; 48():18-26. PubMed ID: 24447521
[TBL] [Abstract][Full Text] [Related]
32. Using different criteria to diagnose (central) auditory processing disorder: how big a difference does it make?
Wilson WJ; Arnott W
J Speech Lang Hear Res; 2013 Feb; 56(1):63-70. PubMed ID: 22761321
[TBL] [Abstract][Full Text] [Related]
33. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis.
Plotkin SR; Bredella MA; Cai W; Kassarjian A; Harris GJ; Esparza S; Merker VL; Munn LL; Muzikansky A; Askenazi M; Nguyen R; Wenzel R; Mautner VF
PLoS One; 2012; 7(4):e35711. PubMed ID: 22558206
[TBL] [Abstract][Full Text] [Related]
34. Plexiform neurofibromas in children with neurofibromatosis type 1: frequency and associated clinical deficits.
Nguyen R; Kluwe L; Fuensterer C; Kentsch M; Friedrich RE; Mautner VF
J Pediatr; 2011 Oct; 159(4):652-5.e2. PubMed ID: 21621223
[TBL] [Abstract][Full Text] [Related]
35. GIN (Gaps-In-Noise) performance in the pediatric population.
Shinn JB; Chermak GD; Musiek FE
J Am Acad Audiol; 2009 Apr; 20(4):229-38. PubMed ID: 19927695
[TBL] [Abstract][Full Text] [Related]
36. GIN (Gaps-In-Noise) test performance in subjects with confirmed central auditory nervous system involvement.
Musiek FE; Shinn JB; Jirsa R; Bamiou DE; Baran JA; Zaida E
Ear Hear; 2005 Dec; 26(6):608-18. PubMed ID: 16377996
[TBL] [Abstract][Full Text] [Related]
37. The nature and frequency of cognitive deficits in children with neurofibromatosis type 1.
Hyman SL; Shores A; North KN
Neurology; 2005 Oct; 65(7):1037-44. PubMed ID: 16217056
[TBL] [Abstract][Full Text] [Related]
38. Development of a 500-Hz masking-level difference protocol for clinic use.
Wilson RH; Moncrieff DW; Townsend EA; Pillion AL
J Am Acad Audiol; 2003; 14(1):1-8. PubMed ID: 12833923
[TBL] [Abstract][Full Text] [Related]
39. Neurofibromatosis type 1.
North K
Am J Med Genet; 2000; 97(2):119-27. PubMed ID: 11180219
[TBL] [Abstract][Full Text] [Related]
40. Development and standardization of SCAN-C Test for Auditory Processing Disorders in Children.
Keith RW
J Am Acad Audiol; 2000 Sep; 11(8):438-45. PubMed ID: 11012239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
